Symbols

INAB

In8bio·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About INAB

In8bio, Inc.

A clinical-stage biopharmaceutical company that focused on gamma-delta T cell product candidates for solid and liquid tumors

Industry

Pharmaceutical

Established Date

05/07/2018

Listing Date

07/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.in8bio.com

Security Type

Common stock

Office address

350 5th Avenue, Suite 5330 , New York, New York 10118

Business

Introduction

In8 bio, Inc., was incorporated in Bermuda on February 8, 2016. On May 7, 2018, the company was reincorporated into the United States in a transaction in which the company was transformed into a newly formed Delaware company, a clinical-stage biotechnology company focused on the discovery, development and commercialization of gamma-delta T cell candidates for solid and liquid tumors.

Company Financials

EPS

INAB has released its 2025 Q3 earnings. EPS was reported at -0.85, versus the expected -1.25, beating expectations. The chart below visualizes how INAB has performed over recent quarters, highlighting trends in earnings surprises.